UY25101A1 - Método para el tratamiento de la diabetes mellitus y las condiciones asociadas - Google Patents

Método para el tratamiento de la diabetes mellitus y las condiciones asociadas

Info

Publication number: UY25101A1
Authority: UY; Uruguay
Prior art keywords: diabetes mellitus; insulin; mammal; alpha; treatment
Prior art date: 1997-07-18

Application number

UY25101A

Other languages

English (en)

Spanish (es)

Inventor

Stephen Smith

Robin Buckingham

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-18

Filing date

1998-07-17

Publication date

2000-12-29

1998-07-17 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2000-12-29 Publication of UY25101A1 publication Critical patent/UY25101A1/es

Links

206010012601 diabetes mellitus Diseases 0.000 title abstract 3
229940122199 Insulin secretagogue Drugs 0.000 abstract 2
229940122355 Insulin sensitizer Drugs 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 2
239000003472 antidiabetic agent Substances 0.000 abstract 2
XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical group O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 abstract 1
LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 abstract 1
RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 abstract 1
FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 abstract 1
FMAZQSYXRGRESX-UHFFFAOYSA-N Glycidamide Chemical compound NC(=O)C1CO1 FMAZQSYXRGRESX-UHFFFAOYSA-N 0.000 abstract 1
102100024295 Maltase-glucoamylase Human genes 0.000 abstract 1
IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 abstract 1
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical group C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 abstract 1
229960002632 acarbose Drugs 0.000 abstract 1
XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 abstract 1
108010028144 alpha-Glucosidases Proteins 0.000 abstract 1
229960001761 chlorpropamide Drugs 0.000 abstract 1
229950000269 emiglitate Drugs 0.000 abstract 1
NWWORXYTJRPSMC-QKPAOTATSA-N ethyl 4-[2-[(2r,3r,4r,5s)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]ethoxy]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 NWWORXYTJRPSMC-QKPAOTATSA-N 0.000 abstract 1
229960004580 glibenclamide Drugs 0.000 abstract 1
229960001764 glibornuride Drugs 0.000 abstract 1
RMTYNAPTNBJHQI-LLDVTBCESA-N glibornuride Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)N[C@H]1[C@H](C2(C)C)CC[C@@]2(C)[C@H]1O RMTYNAPTNBJHQI-LLDVTBCESA-N 0.000 abstract 1
229960004346 glimepiride Drugs 0.000 abstract 1
WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 abstract 1
229960001381 glipizide Drugs 0.000 abstract 1
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 abstract 1
229960003468 gliquidone Drugs 0.000 abstract 1
229950008402 glisentide Drugs 0.000 abstract 1
NSJYMFYVNWVGON-UHFFFAOYSA-N glisentide Chemical compound COC1=CC=CC=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCC2)C=C1 NSJYMFYVNWVGON-UHFFFAOYSA-N 0.000 abstract 1
229950005319 glisolamide Drugs 0.000 abstract 1
GZKDXUIWCNCNBJ-UHFFFAOYSA-N glisolamide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NC2CCCCC2)=N1 GZKDXUIWCNCNBJ-UHFFFAOYSA-N 0.000 abstract 1
229960003236 glisoxepide Drugs 0.000 abstract 1
ZKUDBRCEOBOWLF-UHFFFAOYSA-N glisoxepide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NN2CCCCCC2)=N1 ZKUDBRCEOBOWLF-UHFFFAOYSA-N 0.000 abstract 1
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical group COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 abstract 1
-1 glycopiamide Chemical compound 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
229960001110 miglitol Drugs 0.000 abstract 1
231100000252 nontoxic Toxicity 0.000 abstract 1
230000003000 nontoxic effect Effects 0.000 abstract 1
229960002354 repaglinide Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)

UY25101A 1997-07-18 1998-07-17 Método para el tratamiento de la diabetes mellitus y las condiciones asociadas UY25101A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB9715298A GB9715298D0 (en)	1997-07-18	1997-07-18	Novel method of treatment

Publications (1)

Publication Number	Publication Date
UY25101A1 true UY25101A1 (es)	2000-12-29

Family

ID=10816170

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UY25101A UY25101A1 (es)	1997-07-18	1998-07-17	Método para el tratamiento de la diabetes mellitus y las condiciones asociadas

Country Status (27)

Country	Link
EP (1)	EP1001784A1 (fr)
JP (1)	JP2001510160A (fr)
KR (1)	KR20010021952A (fr)
CN (1)	CN1263467A (fr)
AP (1)	AP2000001735A0 (fr)
AR (2)	AR016350A1 (fr)
AU (1)	AU8449098A (fr)
BG (1)	BG104062A (fr)
BR (1)	BR9810292A (fr)
CA (1)	CA2297133A1 (fr)
CO (1)	CO4940489A1 (fr)
DZ (1)	DZ2563A1 (fr)
EA (1)	EA200000140A1 (fr)
GB (1)	GB9715298D0 (fr)
HU (1)	HUP0003626A3 (fr)
ID (1)	ID23804A (fr)
IL (1)	IL133907A0 (fr)
MA (1)	MA24608A1 (fr)
NO (1)	NO20000230L (fr)
OA (1)	OA11312A (fr)
PE (1)	PE99499A1 (fr)
PL (1)	PL338140A1 (fr)
SK (1)	SK612000A3 (fr)
TR (1)	TR200000133T2 (fr)
UY (1)	UY25101A1 (fr)
WO (1)	WO1999003478A1 (fr)
ZA (1)	ZA986364B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW438587B (en) *	1995-06-20	2001-06-07	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
US7045519B2 (en)	1998-06-19	2006-05-16	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
US6660716B1 (en) *	1999-06-21	2003-12-09	Eli Lilly And Company	Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagon-like peptide-1 and agonists thereof
DK1248604T4 (da) *	2000-01-21	2012-05-21	Novartis Ag	Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
US20030040490A1 (en) *	2000-02-24	2003-02-27	Yasuo Sugiyama	Drugs containing combined active ingredients
JP4917712B2 (ja) *	2000-02-24	2012-04-18	武田薬品工業株式会社	併用医薬
CA2725833A1 (fr)	2001-01-12	2002-07-18	Sun Pharmaceutical Industries Limited	Systeme de liberation espacee de medicaments
FR2832930A1 (fr) *	2001-12-03	2003-06-06	Lipha	Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
GEP20084570B (en)	2003-10-31	2008-12-25	Takeda Pharmaceutical	Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
CN101103993B (zh) *	2006-07-14	2011-03-30	北京华安佛医药研究中心有限公司	降糖药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69219136T2 (de) *	1991-08-26	1997-08-28	Pharmacia & Upjohn Co., Kalamazoo, Mich.	Flüssiges nahrungsmittel, das 3-guanidinopropionsäure enthält
US5917052A (en) *	1994-09-28	1999-06-29	Shaman Pharmaceuticals, Inc.	Hypoglycemic agent from cryptolepis
TW438587B (en) *	1995-06-20	2001-06-07	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes

1997
- 1997-07-18 GB GB9715298A patent/GB9715298D0/en active Pending
1998
- 1998-07-15 DZ DZ980173A patent/DZ2563A1/fr active
- 1998-07-16 EA EA200000140A patent/EA200000140A1/ru unknown
- 1998-07-16 AR ARP980103482A patent/AR016350A1/es unknown
- 1998-07-16 HU HU0003626A patent/HUP0003626A3/hu unknown
- 1998-07-16 TR TR2000/00133T patent/TR200000133T2/xx unknown
- 1998-07-16 WO PCT/GB1998/002112 patent/WO1999003478A1/fr not_active Ceased
- 1998-07-16 CA CA002297133A patent/CA2297133A1/fr not_active Abandoned
- 1998-07-16 MA MA25172A patent/MA24608A1/fr unknown
- 1998-07-16 KR KR1020007000517A patent/KR20010021952A/ko not_active Withdrawn
- 1998-07-16 PL PL98338140A patent/PL338140A1/xx unknown
- 1998-07-16 CN CN98807147A patent/CN1263467A/zh active Pending
- 1998-07-16 SK SK61-2000A patent/SK612000A3/sk unknown
- 1998-07-16 IL IL13390798A patent/IL133907A0/xx unknown
- 1998-07-16 AU AU84490/98A patent/AU8449098A/en not_active Abandoned
- 1998-07-16 EP EP98935129A patent/EP1001784A1/fr not_active Withdrawn
- 1998-07-16 BR BR9810292-3A patent/BR9810292A/pt not_active IP Right Cessation
- 1998-07-16 JP JP2000502777A patent/JP2001510160A/ja active Pending
- 1998-07-16 ID IDW20000077A patent/ID23804A/id unknown
- 1998-07-16 PE PE1998000630A patent/PE99499A1/es not_active Application Discontinuation
- 1998-07-17 ZA ZA9806364A patent/ZA986364B/xx unknown
- 1998-07-17 CO CO98040749A patent/CO4940489A1/es unknown
- 1998-07-17 UY UY25101A patent/UY25101A1/es not_active Application Discontinuation
1999
- 1999-06-28 AR ARP990103110A patent/AR019724A2/es unknown
2000
- 2000-01-06 BG BG104062A patent/BG104062A/xx unknown
- 2000-01-14 AP APAP/P/2000/001735A patent/AP2000001735A0/en unknown
- 2000-01-17 NO NO20000230A patent/NO20000230L/no not_active Application Discontinuation
- 2000-01-18 OA OA1200000013A patent/OA11312A/en unknown

Also Published As

Publication number	Publication date
SK612000A3 (en)	2000-07-11
CA2297133A1 (fr)	1999-01-28
KR20010021952A (ko)	2001-03-15
BG104062A (en)	2000-11-30
DZ2563A1 (fr)	2003-02-15
AP2000001735A0 (en)	2000-01-16
HUP0003626A3 (en)	2001-12-28
GB9715298D0 (en)	1997-09-24
HUP0003626A2 (hu)	2001-05-28
WO1999003478A1 (fr)	1999-01-28
AU8449098A (en)	1999-02-10
PE99499A1 (es)	1999-12-18
PL338140A1 (en)	2000-09-25
NO20000230D0 (no)	2000-01-17
AR019724A2 (es)	2002-03-13
ID23804A (id)	2000-05-11
EA200000140A1 (ru)	2000-06-26
IL133907A0 (en)	2001-04-30
AR016350A1 (es)	2001-07-04
CN1263467A (zh)	2000-08-16
JP2001510160A (ja)	2001-07-31
MA24608A1 (fr)	1999-04-01
CO4940489A1 (es)	2000-07-24
OA11312A (en)	2003-10-24
BR9810292A (pt)	2000-09-19
NO20000230L (no)	2000-01-17
EP1001784A1 (fr)	2000-05-24
ZA986364B (en)	2000-01-17
TR200000133T2 (tr)	2000-09-21

Legal Events

Date	Code	Title	Description
2012-12-07	109	Application deemed to be withdrawn	Effective date: 20121207

Publication	Publication Date	Title
MY129897A (en)	2007-05-31	Use of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione and metformin for the treatment of diabetes mellitus
AR057970A2 (es)	2007-12-26	Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus y procedimientos para preprar dichas composiciones
PE99599A1 (es)	1999-12-18	Composicion farmaceutica para el tratamiento de la diabetes
UY25799A1 (es)	2000-12-29	Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina y otro agente antidiabético.
UY24893A1 (es)	1998-07-10	Combinaciones para diabetes de sulfonilurea glitazona
HK1053788A1 (zh)	2003-11-07	Ppar-gamma拮抗劑在中性粒細胞-誘導的疾病中的用途
NO20083276L (no)	2000-02-17	Behandling av diabetes med tiazolidindion og sulfonylurea
AR012997A1 (es)	2000-11-22	Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4- diona e insulina para la preparacion de medicamentos, y composicionfarmaceutica que los contiene.
PE99499A1 (es)	1999-12-18	Composicion farmaceutica para el tratamiento de la diabetes
AR008198A1 (es)	1999-12-29	Procedimiento para preparar una composicion farmaceutica de 5-[4-[2-(n- metil-n-(2-piridil)amino)etoxi]bencil]tiazolin-2,4-diona
AR045230A1 (es)	2005-10-19	Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2- piridil)-amino)-etoxi]-bencil]-tiazolidino-2,4-diona y otro agente antidiabetico adicional; procedimiento para su preparacion y uso de 5-[4-[2-(metil-n-(2-piridil)-amino)-etoxi]- bencil]- tiazolidino-2,4-diona y otro agente antidiabetic
PE89199A1 (es)	1999-10-23	Composicion farmaceutica de tiazolidinadiona y un inhibidor de alfa glucosidasa para el tratamiento de la diabetes
AR016768A1 (es)	2001-08-01	COMPOSICIoN FARMACÉUTICA DE 5-(4- (2-(N-METIL-N-(2-PIRIDIL) AMINO)ETOXI)BENCIL)TIAZOLIDIN-2-4-DIONA Y UN SECRETAGOGO DE INSULINA Y USO DE LA MISMA PARA PREPARACIoN DE MEDICAMENTOS
AR104503A2 (es)	2017-07-26	Compuestos heterocíclicos de ácido borónico
BR0111536A (pt)	2003-07-01	Sal de tiazolidinediona para tratamento de diabetes mellitus
NO20075507L (no)	2003-05-27	Tiazolidindionderivater og deres anvendelse som antidiabetiske midler
DK1315724T3 (da)	2006-02-20	Thiazolidindionderivat og dets anvendelse som antidiabetikum
ECSP982535A (es)	1999-04-13	Nuevo metodo de tratamiento (i)
ECSP982591A (es)	1999-02-22	Nuevo metodo de tratamiento iv
RU2021105658A (ru)	2022-09-09	Способы отсрочки возникновения диабета 2 типа и замедления прогрессии, и лечения диабета 2 типа
ECSP982541A (es)	1999-02-11	Nuevo metodo de tratamiento ii
Zacho	2016	Insulin/GLP-1 Treatment for Patients with DM
TH36757A (th)	2000-01-14	กรรมวิธีในการรักษาเบาหวานด้วยไธอะโซลิดีนไดโอนและซัลโฟนิลยูเรีย
ECSP982593A (es)	1999-02-22	Nuevo metodo de tratamiento vi
TH21154B (th)	2006-12-28	กรรมวิธีในการรักษาโรคเบาหวานด้วยไธอะโซลิดีนไดโอนและเมทฟอร์มิน